Rhythm Pharmaceuticals (RYTM) News Today $56.07 -1.67 (-2.89%) Closing price 04:00 PM EasternExtended Trading$54.74 -1.33 (-2.37%) As of 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Christopher Paul German Sells 635 SharesRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) CAO Christopher Paul German sold 635 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $57.22, for a total transaction of $36,334.70. Following the completion of the transaction, the chief accounting officer now directly owns 2,070 shares of the company's stock, valued at approximately $118,445.40. This represents a 23.48 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.February 20 at 11:18 PM | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells $70,266.16 in StockRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) insider Joseph Shulman sold 1,228 shares of the company's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $57.22, for a total value of $70,266.16. Following the completion of the transaction, the insider now directly owns 8,509 shares of the company's stock, valued at $486,884.98. This represents a 12.61 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.February 20 at 11:18 PM | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Jennifer Kayden Lee Sells 2,035 SharesRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) EVP Jennifer Kayden Lee sold 2,035 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $57.22, for a total value of $116,442.70. Following the completion of the transaction, the executive vice president now owns 5,858 shares in the company, valued at $335,194.76. The trade was a 25.78 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.February 20 at 11:18 PM | marketbeat.comHunter C. Smith Sells 2,215 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) StockRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) CFO Hunter C. Smith sold 2,215 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $57.22, for a total value of $126,742.30. Following the completion of the sale, the chief financial officer now directly owns 109,929 shares in the company, valued at $6,290,137.38. This represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.February 20 at 11:18 PM | marketbeat.comDavid P. Meeker Sells 9,896 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) StockRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) CEO David P. Meeker sold 9,896 shares of the firm's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $57.22, for a total transaction of $566,249.12. Following the transaction, the chief executive officer now directly owns 201,281 shares in the company, valued at approximately $11,517,298.82. The trade was a 4.69 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.February 20 at 11:18 PM | marketbeat.comRhythm Pharmaceuticals' (RYTM) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $64.00 price target on shares of Rhythm Pharmaceuticals in a report on Wednesday.February 20 at 8:05 AM | marketbeat.comInsider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Sells 635 Shares of StockFebruary 20 at 5:41 AM | insidertrades.comRhythm Pharmaceuticals (RYTM) Expected to Announce Quarterly Earnings on ThursdayRhythm Pharmaceuticals (NASDAQ:RYTM) will be releasing earnings before the market opens on Thursday, February 27. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=666123)February 20 at 2:16 AM | marketbeat.comCannon Financial Strategists Inc. Invests $560,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Cannon Financial Strategists Inc. purchased a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 10,000 shares of the company's stock, valued at approximatelyFebruary 19 at 6:37 AM | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Jennifer Kayden Lee Sells 1,815 SharesRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) EVP Jennifer Kayden Lee sold 1,815 shares of the stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $56.39, for a total transaction of $102,347.85. Following the completion of the sale, the executive vice president now directly owns 3,598 shares in the company, valued at $202,891.22. This trade represents a 33.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.February 15, 2025 | marketbeat.comBrokerages Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Price Target at $68.09February 14, 2025 | americanbankingnews.comRhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025February 13, 2025 | globenewswire.comJoseph Shulman Sells 794 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) StockFebruary 12, 2025 | insidertrades.comEquities Analysts Set Expectations for RYTM FY2029 EarningsFebruary 12, 2025 | americanbankingnews.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells $45,662.94 in StockRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) insider Joseph Shulman sold 794 shares of the stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $57.51, for a total transaction of $45,662.94. Following the completion of the sale, the insider now directly owns 6 shares of the company's stock, valued at approximately $345.06. This trade represents a 99.25 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.February 11, 2025 | marketbeat.comInsider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CFO Sells 1,296 Shares of StockRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) CFO Hunter C. Smith sold 1,296 shares of the firm's stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $57.51, for a total transaction of $74,532.96. Following the transaction, the chief financial officer now directly owns 106,295 shares of the company's stock, valued at $6,113,025.45. This represents a 1.20 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.February 11, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Sells $246,773.99 in StockRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) EVP Jennifer Kayden Lee sold 4,189 shares of the firm's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $58.91, for a total transaction of $246,773.99. Following the sale, the executive vice president now owns 4,409 shares of the company's stock, valued at approximately $259,734.19. The trade was a 48.72 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.February 11, 2025 | marketbeat.comResearch Analysts Set Expectations for RYTM FY2029 EarningsRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - Research analysts at Needham & Company LLC issued their FY2029 earnings per share (EPS) estimates for Rhythm Pharmaceuticals in a report released on Thursday, February 6th. Needham & Company LLC analyst J. Stringer expects that the companFebruary 10, 2025 | marketbeat.comabrdn plc Has $4.51 Million Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)abrdn plc trimmed its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 28.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 80,517 shares of the company's stock after seFebruary 10, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eleven analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating and ten have assignFebruary 7, 2025 | marketbeat.comRhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in FebruaryFebruary 5, 2025 | finance.yahoo.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Joseph Shulman Sells 1,281 SharesFebruary 5, 2025 | insidertrades.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells $76,129.83 in StockRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) insider Joseph Shulman sold 1,281 shares of the business's stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $59.43, for a total value of $76,129.83. Following the transaction, the insider now owns 2,657 shares in the company, valued at approximately $157,905.51. This trade represents a 32.53 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.February 4, 2025 | marketbeat.comJennifer Kayden Lee Sells 1,447 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) StockRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) EVP Jennifer Kayden Lee sold 1,447 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $59.43, for a total value of $85,995.21. Following the sale, the executive vice president now directly owns 4,038 shares in the company, valued at $239,978.34. This trade represents a 26.38 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.February 4, 2025 | marketbeat.comInsider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CFO Sells 1,678 Shares of StockRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) CFO Hunter C. Smith sold 1,678 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $59.43, for a total value of $99,723.54. Following the completion of the transaction, the chief financial officer now owns 101,186 shares of the company's stock, valued at $6,013,483.98. The trade was a 1.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.February 4, 2025 | marketbeat.comDavid P. Meeker Sells 4,278 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) StockRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) CEO David P. Meeker sold 4,278 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $59.43, for a total transaction of $254,241.54. Following the completion of the sale, the chief executive officer now owns 189,927 shares of the company's stock, valued at $11,287,361.61. This trade represents a 2.20 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.February 4, 2025 | marketbeat.comJGP Global Gestao de Recursos Ltda. Cuts Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)JGP Global Gestao de Recursos Ltda. reduced its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 90.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,378 shares of the compFebruary 3, 2025 | marketbeat.comInteresting RYTM Put And Call Options For March 21stJanuary 31, 2025 | nasdaq.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Nisa Investment Advisors LLCNisa Investment Advisors LLC reduced its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 98.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,285 shares of the company'January 31, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Sees Large Volume Increase - Still a Buy?Rhythm Pharmaceuticals (NASDAQ:RYTM) Sees Large Volume Increase - Should You Buy?January 21, 2025 | marketbeat.comEarnings call transcript: Rhythm Pharmaceuticals Q3 2024 sees growthJanuary 21, 2025 | msn.comJPMorgan Chase & Co. Sells 58,554 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)JPMorgan Chase & Co. decreased its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 41.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 81,592 shares of the company's sJanuary 18, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Recommendation of "Moderate Buy" by AnalystsRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eleven ratings firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating and ten have given a buy ratingJanuary 13, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Harbor Capital Advisors Inc.Harbor Capital Advisors Inc. trimmed its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 26.9% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 30,252 shares of the company's stock after selling 11,116 shares duriJanuary 13, 2025 | marketbeat.comRhythm Pharmaceuticals price target raised to $60 from $58 at BofAJanuary 12, 2025 | markets.businessinsider.comRhythm Pharmaceuticals’ Strong Sales and Clinical Advancements Justify Buy RatingJanuary 11, 2025 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Rhythm Pharmaceuticals (RYTM)January 10, 2025 | markets.businessinsider.comRhythm Pharmaceuticals: Strong Financial Performance and Promising Pipeline Drive Buy RatingJanuary 10, 2025 | markets.businessinsider.comRhythm Pharmaceuticals Expects Higher Product Revenue For Full-yearJanuary 10, 2025 | markets.businessinsider.comRhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming MilestonesJanuary 10, 2025 | globenewswire.comPrincipal Financial Group Inc. Has $1.71 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Principal Financial Group Inc. raised its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 241.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32January 5, 2025 | marketbeat.comJefferies Financial Group Begins Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM)Jefferies Financial Group initiated coverage on shares of Rhythm Pharmaceuticals in a report on Thursday. They issued a "buy" rating and a $80.00 price objective on the stock.January 2, 2025 | marketbeat.comJefferies starts Rhythm Pharmaceuticals with Buy on obesity potentialJanuary 1, 2025 | markets.businessinsider.comRhythm Pharmaceuticals initiated with a Buy at JefferiesJanuary 1, 2025 | markets.businessinsider.comRhythm Pharmaceuticals (NASDAQ:RYTM) Sees Large Volume Increase - What's Next?Rhythm Pharmaceuticals (NASDAQ:RYTM) Sees Strong Trading Volume - Still a Buy?December 23, 2024 | marketbeat.comRhythm Pharmaceuticals' (NASDAQ:RYTM) investors will be pleased with their incredible 370% return over the last three yearsDecember 23, 2024 | uk.finance.yahoo.comRhythm Pharmaceuticals’ Promising Future: Buy Rating Reiterated Amid FDA Approval and Strategic ExpansionDecember 23, 2024 | markets.businessinsider.comRhythm Pharmaceuticals (NASDAQ:RYTM) Given "Market Outperform" Rating at JMP SecuritiesJMP Securities restated a "market outperform" rating and set a $75.00 target price on shares of Rhythm Pharmaceuticals in a research report on Monday.December 23, 2024 | marketbeat.comRhythm Pharmaceuticals' (RYTM) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and set a $69.00 price target on shares of Rhythm Pharmaceuticals in a research note on Monday.December 23, 2024 | marketbeat.comRhythm Pharmaceuticals initiated with an Outperform at OppenheimerDecember 21, 2024 | markets.businessinsider.com Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address RYTM Media Mentions By Week RYTM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RYTM News Sentiment▼0.240.60▲Average Medical News Sentiment RYTM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RYTM Articles This Week▼177▲RYTM Articles Average Week Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Intra-Cellular Therapies News Today Viatris News Today Moderna News Today Dr. Reddy's Laboratories News Today Vaxcyte News Today Sarepta Therapeutics News Today Qiagen News Today Ascendis Pharma A/S News Today Roivant Sciences News Today Revolution Medicines News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RYTM) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
